Drug Trial Radar · NCT05222529
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Glycopyrronium (Bromide) in Children (6 to Less Than 12 Years) With Asthma
Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
42
Planned (sponsor's estimate)
Start
Aug 29, 2022
Primary completion
Jul 30, 2027
Study completion Aug 30, 2027
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Feb 3, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 6 years, up to 11 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to characterize the bronchodilator effect, systemic exposure and safety/tolerability of two different doses of inhaled glycopyrronium, when compared to placebo. Outcome of this study will be used to determine the dose of inhaled glycopyrronium for the development of fixed dose combination indacaterol/mometasone/glycopyrronium (QVM149) for children aged 6 to less than 12 years old with moderate to severe asthma.
Conditions
- Asthma
Interventions
Glycopyrronium bromide 25ugDrug
25μg Glycopyrronium bromide capsules for oral inhalation via Breezhaler
PlaceboDrug
Placebo to Glycopyrronium bromide capsules for oral inhalation via Breezhaler
Glycopyrronium bromide 12.5ugDrug
12.5ug Glycopyrronium bromide capsules for oral inhalation via Breezhaler
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from Baseline in trough FEV1Time frame: At the start and end of each 2 week treatment period (Days 1, 14, 29, 42, 57 and 70)
Locations
23 sites in 8 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Rousse, Bulgaria · Recruiting
Novartis Investigative Site
Sevlievo, Bulgaria · Recruiting
Novartis Investigative Site
Sofia, Bulgaria · Recruiting
Novartis Investigative Site
Ibague, Tolima Department, Colombia · Recruiting
Novartis Investigative Site
Guatemala City, Guatemala · Recruiting
Novartis Investigative Site
Guatemala City, GTM, Guatemala · Withdrawn
Novartis Investigative Site
Budapest, Hungary · Recruiting
Novartis Investigative Site
Budapest, Hungary · Recruiting
Novartis Investigative Site
Eger, Hungary · Recruiting
Novartis Investigative Site
Kaposvár, Hungary · Withdrawn
Novartis Investigative Site
Nagykanizsa, Hungary · Withdrawn
Novartis Investigative Site
Szigetvár, Hungary · Recruiting
Novartis Investigative Site
Debrecen, Hajdu Bihar Megye, Hungary · Recruiting
Novartis Investigative Site
Lodz, Łódź Voivodeship, Poland · Recruiting
Novartis Investigative Site
Tarnów, Poland, Poland · Recruiting
Novartis Investigative Site
Cape Town, South Africa · Recruiting
Novartis Investigative Site
George, Western Cape, South Africa · Recruiting
Novartis Investigative Site
Barcelona, Spain · Recruiting
Novartis Investigative Site
Esplugues, Barcelona, Spain · Recruiting
Novartis Investigative Site
Sabadell, Barcelona, Spain · Recruiting
Novartis Investigative Site
Mérida, Extremadura, Spain · Withdrawn
Novartis Investigative Site
London, United Kingdom · Recruiting
Novartis Investigative Site
Stoke-on-Trent, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.